Institutul Regional De Gastroenterologie Hepatologie Prof. Dr. Octavian Fodor Cluj

At Institutul Regional De Gastroenterologie Hepatologie Prof. Dr. Octavian Fodor Cluj, a major focus is on digestive system diseases and liver disorders. The trials include studies in cirrhosis, non-alcoholic steatohepatitis, metabolic dysfunction-associated steatotic liver disease, and hepatitis B, with the goal of improving treatment effectiveness, reducing complications, and exploring new ways to protect liver function.

• Research in cirrhosis and portal hypertension aims to better control disease progression and related risks.
• Studies in NASH and fatty liver disease are evaluating potential therapies that may improve liver health and clinical outcomes.
• Trials in chronic hepatitis B are focused on advancing approaches that may support long-term control or functional cure.

This research area reflects the site’s strong role in addressing chronic hepatology conditions with practical relevance for patients and clinicians.

The site also conducts extensive research in neoplasms, especially gastric cancer, gastroesophageal junction adenocarcinoma, colorectal cancer, and cholangiocarcinoma. These studies are designed to test new treatment strategies and improve outcomes for people with advanced digestive tract cancers.

• Trials in gastric and gastroesophageal junction cancers are evaluating new combinations to strengthen first-line treatment.
• Research in colorectal cancer is examining whether novel therapies can better control tumor growth.
• Studies in cholangiocarcinoma are assessing new options for patients with difficult-to-treat disease.

This oncology portfolio shows a clear interest in testing more effective therapies for advanced gastrointestinal malignancies.

A substantial part of the research landscape is centered on immune system diseases, especially ulcerative colitis and Crohn’s disease. These trials are aimed at improving symptom control, achieving remission, and supporting longer-term disease management in people with chronic intestinal inflammation.

• Studies in ulcerative colitis are evaluating therapies intended to induce and maintain remission.
• Research in Crohn’s disease is focused on treatment effectiveness and sustained disease control.
• Additional work looks at broader inflammatory bowel disease management and patient response over time.

These trials highlight the site’s strong commitment to advancing care in gastroenterology and chronic inflammatory disease.

The site participates in studies within respiratory tract diseases and immune-related allergic conditions, including asthma, seasonal allergic rhinitis, and chronic inducible urticaria. The purpose of this research is to improve symptom relief, reduce flare-ups, and evaluate new treatment options for patients with persistent allergic or airway disease.

• Asthma trials are examining ways to improve control and reduce exacerbations.
• Allergy studies are focused on grass pollen-induced rhinitis and related symptoms.
• Urticaria research is assessing therapies for difficult-to-control chronic hives.

This area broadens the site’s research profile beyond digestive disease into chronic airway and allergic disorders.

Additional trials address hemic and lymphatic diseases, nutritional and metabolic diseases, and selected rare conditions. Research includes cancer-associated thrombosis, hereditary hemochromatosis, and hereditary angioedema, with studies designed to prevent complications, improve diagnosis, or test new treatment approaches.

• Trials in cancer-associated thrombosis are evaluating prevention of clotting events in patients with cancer.
• Studies in hereditary hemochromatosis are looking at ways to reduce excess iron and protect organs.
• Research in hereditary angioedema is focused on better control of acute attacks and symptom relief.

These studies add important breadth to the portfolio at Institutul Regional De Gastroenterologie Hepatologie Prof. Dr. Octavian Fodor Cluj, linking chronic disease care with rare-disease research.